Weight Loss Drug Tirzepatide Linked to Reduced Risk of Diabetic Retinopathy
The popular medications tirzepatide (Mounjaro or Zepbound), used for both diabetes management and weight loss, may lower the risk of diabetic retinopathy, a leading cause of vision loss, according to research from Weill Cornell Medicine. This finding offers reassurance to patients concerned about potential eye health impacts while taking these drugs.
Understanding Diabetic Retinopathy
Diabetic retinopathy develops when high blood sugar levels damage blood vessels in the retina, the light-sensitive tissue at the back of the eye. It affects nearly 10 million people in the United States.
Previous Concerns and the New Findings
Prior studies raised concerns that GLP-1 based diabetes and weight-loss drugs, such as semaglutide (Wegovy or Ozempic), could potentially worsen diabetic retinopathy. However, the recent findings, published in Ophthalmology on January 21, 2026, indicate that patients taking tirzepatide were significantly less likely to develop new diabetic retinopathy or experience progression to more severe stages of the disease.
How Tirzepatide Works
More than 6 million Americans are currently using either semaglutide or tirzepatide. GLP-1 agonists, like semaglutide, function by mimicking the natural hormone glucagon-like peptide-1 (GLP-1), which stimulates insulin secretion and suppresses glucagon, a hormone that elevates blood sugar. Tirzepatide, however, goes a step further by activating both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) pathway. This dual action leads to greater improvements in insulin sensitivity, weight loss, and metabolic inflammation.
Study Details and Results
Researchers at Weill Cornell Medicine analyzed electronic health records from approximately 174,000 patients across 70 U.S. Health systems. They compared patients with diabetes and obesity who initiated tirzepatide treatment to a control group receiving lifestyle interventions like dietary guidance and exercise counseling.
After one year, patients taking tirzepatide demonstrated a lower risk of worsening diabetic retinopathy or related complications compared to the control group. Specifically, the incidence of mild nonproliferative diabetic retinopathy was 0.49% in the tirzepatide group versus 1.2% in the control group. The tirzepatide group required fewer eye treatments, such as intraocular injections or laser therapy.
Expert Perspectives
“Based on findings from a large database of patients across multiple clinical practices, those with diabetic retinopathy may be less concerned that taking tirzepatide is going to make their condition worse,” said Dr. Szilárd Kiss, lead author of the study and an ophthalmologist at NewYork-Presbyterian/Weill Cornell Medical Center.
Jaffer Shah, clinical trials coordinator at Weill Cornell and co-author of the study, added, “Our study and others suggest that drugs like semaglutide and tirzepatide may not affect diabetic retinopathy in the same way. Understanding differences in broader metabolic changes, including possible effects on retinal microvasculature, is of interest as this could guide treatment choices with long-term eye health in mind.”
Future Research
Dr. Kiss plans to collaborate with Dr. Kyle Kovacs to gather more detailed patient data, including retinal images and anatomical measurements, for future investigations.